Summary of key results with 95% Credible Intervals
| Elimination | Eradication I | Eradication II | Eradication III | |
|---|---|---|---|---|
| Number of treatments (millions) | 3.41 (3.18–3.53) | 4.66 (4.41–4.90) | 4.37 (4.13–4.59) | 4.16 (3.92–4.38) |
| DALYs averted (millions)* | – | 1.72 (1.09–2.62) | 2.98 (1.90–4.45) | 4.38 (2.79–6.50) |
| Financial costs (millions USD) | 929.2 (883.5–971.5) | 1289.4 (1226.7–1344.9) | 1273.5 (1208.9–1331.4) | 1234.9 (1172.3–1299.8) |
| Economic costs (billions USD) | 5.19 (4.91–5.45) | 7.91 (7.50–8.300) | 7.97 (7.55–8.37) | 7.53 (7.12–7.94) |
| ICER (USD/DALY averted)* | – | 219.0 (142.65–322.72) | 120.7 (79.47–177.70) | 72.94 (47.74–109.80) |
| Potential savings to health system (millions USD)* | – | 139.9 (63.8–260.3) | 335.6 (152.2–626.8) | 483.4 (219.1–902.6) |
| Potential gains in worker productivity (billions USD)* | – | 3.41 (2.03–5.36) | 10.06 (5.98–15.50) | 14.43 (8.58–22.02) |
*Measured against the elimination scenario as the comparator.
DALY, disability adjusted life years; ICER, incremental cost-effectiveness ratios.